Retinopathy Pigmentary Mental Retardation Overview

Save information for later
Sign Up

Learn About Retinopathy Pigmentary Mental Retardation

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Retinopathy Pigmentary Mental Retardation Local Doctors?
Elite in Retinopathy Pigmentary Mental Retardation
Elite in Retinopathy Pigmentary Mental Retardation

University Of North Carolina At Chapel Hill

2226 Nelson Hwy, Suite 200, 
Chapel Hill, NC 
Languages Spoken:
English
Accepting New Patients

Alessandro Iannaccone is an Ophthalmologist in Chapel Hill, North Carolina. Dr. Iannaccone is rated as an Elite provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, X-Linked Retinitis Pigmentosa (XLRP), and Usher Syndrome Type 2A. Dr. Iannaccone is currently accepting new patients.

Jose' A. Sahel
Elite in Retinopathy Pigmentary Mental Retardation
Ophthalmology
Elite in Retinopathy Pigmentary Mental Retardation
Ophthalmology

UPMC Vision Institute

1622 Locust Street, Floor 2, 
Pittsburgh, PA 
Languages Spoken:
English, French
Accepting New Patients
Offers Telehealth

Jose' Sahel is an Ophthalmologist in Pittsburgh, Pennsylvania. Dr. Sahel is rated as an Elite provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Retinopathy Pigmentary Mental Retardation, X-Linked Congenital Stationary Night Blindness, Cone-Rod Dystrophy, Retinitis Pigmentosa, and Vitrectomy. Dr. Sahel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Peter A. Campochiaro
Elite in Retinopathy Pigmentary Mental Retardation
Elite in Retinopathy Pigmentary Mental Retardation

The Johns Hopkins Hospital

1800 Orleans Street, Maumenee Lobby, Maumenee Lobby, 
Baltimore, MD 
Languages Spoken:
English

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

What are the latest Retinopathy Pigmentary Mental Retardation Clinical Trials?
Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)

Summary: The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

Match to trials
Find the right clinical trials for you in under a minute
Get started
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls

Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells collected from hair follicles, skin, saliva, urine, and blood can be used for research. Researchers want to collect c...